

# Charlotte E Teunissen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4340247/charlotte-e-teunissen-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

523  
papers

16,759  
citations

63  
h-index

113  
g-index

635  
ext. papers

22,357  
ext. citations

5.5  
avg, IF

6.57  
L-index

#	Paper	IF	Citations
523	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
522	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.. <i>Brain Communications</i> , <b>2022</b> , 4, fcac026	4.5	0
521	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103364	4	1
520	CSF proteomic signature predicts progression to Alzheimer's disease dementia.. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , <b>2022</b> , 8, e12240	6	
519	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease.. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19, 50	10.1	1
518	Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	1
517	Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264557	3.7	3
516	NT-proBNP and sRAGE levels in early rheumatoid arthritis.. <i>Scandinavian Journal of Rheumatology</i> , <b>2022</b> , 1-7	1.9	1
515	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 27	19	1
514	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 840651	5.3	0
513	Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.. <i>Neurology</i> , <b>2022</b> , 98, 471	6.5	
512	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2022</b> , 14, e12314	5.2	0
511	Effects of age, amyloid, sex, and $\beta$ on the CSF proteome in normal cognition.. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2022</b> , 14, e12286	5.2	
510	Gut Microbiota Composition Is Related to AD Pathology.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 794519	8.4	7
509	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 805135	4.1	1
508	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease.. <i>Neuron</i> , <b>2021</b> ,	13.9	2
507	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3

506	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17,	1.2	3
505	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 198	9	14
504	Pre-analytical sample handling effects on blood cytokine levels: quality control of a COVID-19 biobank. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 987-997	2.3	
503	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology, The</i> , <b>2021</b> ,	24.1	40
502	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimeris and Dementia</i> , <b>2021</b> ,	1.2	12
501	The global Alzheimer's Association round robin study on plasma amyloid $\beta$ methods. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12242	5.2	2
500	Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials. <i>Neurotherapeutics</i> , <b>2021</b> , 1	6.4	2
499	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
498	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 638718	5.3	2
497	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid $\beta$ and tau. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17, 1575-1582	1.2	12
496	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17, 1452-1464	1.2	4
495	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , <b>2021</b> , 89, 987-1000	9.4	5
494	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	2
493	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211010097	5	4
492	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2021</b> , 7, 20552173211013831	2	1
491	Alzheimer's disease. <i>Lancet, The</i> , <b>2021</b> , 397, 1577-1590	40	245
490	Use of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic. <i>Canadian Journal of Neurological Sciences</i> , <b>2021</b> , 1-7	1	1
489	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 50, 102840	4	1

488	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimeris Disease</i> , <b>2021</b> , 82, 381-390	4.3	2
487	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 101	9	5
486	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimeris and Dementia</i> , <b>2021</b> ,	1.2	6
485	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17, 1628-1640	1.2	4
484	Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. <i>Scientific Reports</i> , <b>2021</b> , 11, 9736	4.9	18
483	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A $\beta$ <sub>42</sub> /A $\beta$ <sub>40</sub> and p-tau. <i>Alzheimeris and Dementia</i> , <b>2021</b> ,	1.2	12
482	The plasma peptides of Alzheimer's disease. <i>Clinical Proteomics</i> , <b>2021</b> , 18, 17	5	2
481	Diagnostic Value of the CSF $\beta$ Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , <b>2021</b> , 97, e930-e940	6.5	9
480	Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 133	9	6
479	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	1
478	Serum Contactin-1 in CIDP: A Cross-Sectional Study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	2
477	Effect of driving speed on target visibility under mesopic conditions using a driving simulator. <i>Lighting Research and Technology</i> , <b>2021</b> , 53, 231-248	2	0
476	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	9
475	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , <b>2021</b> , 27, 426-438	3.1	10
474	Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 47, 102666	4	3
473	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17, 205-214	1.2	3
472	Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12127	6	2
471	Risk of dementia in $\epsilon$ carriers is mitigated by a polygenic risk score. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12229	5.2	2

470	Concatenating plasma p-tau to Alzheimer's disease. <i>Brain</i> , <b>2021</b> , 144, 14-17	11.2	1
469	Biomarker testing in MCI patients-deciding who to test. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 14	9	0
468	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 2	9	5
467	βSynuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia. <i>Glia</i> , <b>2021</b> , 69, 1413-1428	9	18
466	Pre-Analytical Processing and Biobanking Protocol for CSF Samples. <i>NeuroMethods</i> , <b>2021</b> , 137-145	0.4	
465	Targeting hippocampal hyperactivity with real-time fMRI neurofeedback: protocol of a single-blind randomized controlled trial in mild cognitive impairment. <i>BMC Psychiatry</i> , <b>2021</b> , 21, 87	4.2	2
464	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , <b>2021</b> , 32, 573-595	4.7	10
463	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEVELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 53	9	7
462	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 38	9	4
461	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , <b>2021</b> , 2, e87-e95	9.5	21
460	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. <i>Brain</i> , <b>2021</b> ,	11.2	31
459	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211028833	5	11
458	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , <b>2021</b> , 9,	4.6	2
457	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 83, 269-279	4.3	3
456	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. <i>Neurology</i> , <b>2021</b> , 97, e1276-e1287	6.5	8
455	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. <i>Brain</i> , <b>2021</b> ,	11.2	2
454	Head-to-Head Comparison of 8 Plasma Amyloid-β42/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1375-1382	17.2	29
453	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e1898-e1905	6.5	12

452	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , <b>2021</b> , 3, fcab201	4.5	2
451	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , <b>2021</b> , 20, 739-752	24.1	43
450	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 83, 1367-1377	4.3	
449	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , <b>2021</b> , 108, 146-154	5.6	2
448	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , <b>2021</b> , 108, 99-109	5.6	3
447	Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12182	5.2	3
446	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 27	8.6	55
445	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	3
444	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17,	1.2	1
443	Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid.. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17 Suppl 3, e049531	1.2	
442	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17 Suppl 3, e055451	1.2	
441	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e036954	1.2	1
440	CSF proteomic changes in pre-preclinical Alzheimer's disease: A monozygotic twin study. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e038966	1.2	
439	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e039094	1.2	1
438	Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEVELOP baseline results. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e039306	1.2	
437	Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041789	1.2	
436	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042116	1.2	
435	BDNF-Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042728	1.2	

434	Development of an ultrasensitive multiplex assay for simultaneous detection of A $\beta$ -42, A $\beta$ -40, GFAP and NF-L in blood. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e043506	1.2	0
433	Localization and protein levels of YKL-40 in postmortem brain of frontotemporal dementia and Alzheimer's disease cases. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e044523	1.2	
432	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e044783	1.2	
431	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e044787	1.2	
430	Comparison of two analytical platforms for blood-based surrogate biomarkers of amyloid pathology. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045110	1.2	
429	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045112	1.2	
428	Using cerebrospinal fluid amyloid-beta(1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045128	1.2	3
427	Serum neurofilament light in memory clinic practice. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045155	1.2	
426	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045196	1.2	
425	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045230	1.2	0
424	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045470	1.2	
423	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045719	1.2	
422	Plasma amyloid- $\beta$ oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045754	1.2	
421	Comparative diagnostic performance of plasma P-tau217 and P-tau181 in Alzheimer's disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipir-PET uptake. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045755	1.2	
420	A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer's disease: The first results. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045763	1.2	3
419	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045829	1.2	0
418	CSF biomarkers for frontotemporal dementia and its pathological subtypes. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045851	1.2	
417	Prediction of amyloid PET status using the LUMIPULSE G $\beta$ amyloid ratio (1-42/1-40). <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e046006	1.2	1

416	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e046102	1.2	
415	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e047209	1.2	1
414	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e047247	1.2	1
413	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> ,	5.9	5
412	Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 130, 424-432	5.2	7
411	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 138	9	5
410	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ carriers. <i>Scientific Reports</i> , <b>2020</b> , 10, 8233	4.9	4
409	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 74, 213-225	4.3	10
408	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	9
407	APOE $\epsilon$ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 65	9	13
406	ATN classification and clinical progression in subjective cognitive decline: The SCIENCE project. <i>Neurology</i> , <b>2020</b> , 95, e46-e58	6.5	30
405	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 76, 27-31	4.3	5
404	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2020</b> , 21, 452-458	3.6	8
403	High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients. <i>Journal of NeuroVirology</i> , <b>2020</b> , 26, 572-580	3.9	2
402	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , <b>2020</b> , 15, 36	19	16
401	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. <i>Neurobiology of Aging</i> , <b>2020</b> , 93, 144.e1-144.e15	5.6	6
400	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 76, 1061-1070	4.3	4
399	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> , 21, 1436-1438	5.9	0



398	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , <b>2020</b> , 26, 387-397	50.5	236
397	Fingerprinting Alzheimer's Disease by H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , <b>2020</b> , 19, 1696-1705	5.6	17
396	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 73, 1585-1595	4.3	10
395	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. <i>Neurobiology of Aging</i> , <b>2020</b> , 89, 99-107	5.6	18
394	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0226784	3.7	4
393	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 612-621	5.5	22
392	Regional [F]lortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2866-2878	8.8	11
391	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. <i>Biomedicine Hub</i> , <b>2020</b> , 5, 19-40	1.3	2
390	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 118	9	54
389	Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 169	9	10
388	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , <b>2020</b> , 95, e3026-e3035	6.5	13
387	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease <b>2020</b> , ,		1
386	Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. <i>Cells</i> , <b>2020</b> , 10,	7.9	8
385	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12120	5.2	0
384	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> , 21, 1513.e1-1513.e17	5.9	12
383	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 699-710	24.1	35
382	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , <b>2020</b> , 143, 3776-3792	11.2	16
381	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". <i>Annals of Neurology</i> , <b>2020</b> , 87, 155	9.4	2

380	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2020</b> , 57, 86-98	9.4	23
379	CSF or serum neurofilament light added to $\alpha$ -Synuclein panel discriminates Parkinson's from controls. <i>Movement Disorders</i> , <b>2020</b> , 35, 288-295	7	28
378	Why Is Amyloid- $\beta$ -PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 73, 559-569	4.3	5
377	Amyloid- $\beta$ -PET and CSF in an autopsy-confirmed cohort. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 2150-2160	5.3	10
376	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 116	9	9
375	Plasma NFL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 2127-2136	5.3	7
374	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , <b>2020</b> , 95, e1538-e1553	6.5	20
373	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , <b>2020</b> , 95, 436-444	6.5	44
372	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
371	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 403	8.6	10
370	Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test. <i>Brain</i> , <b>2020</b> , 143, 3170-3172	11.2	4
369	Comparison of ELISA- and SIMOA-based quantification of plasma A $\beta$ ratios for early detection of cerebral amyloidosis. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 162	9	21
368	Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. <i>Neurology</i> , <b>2020</b> , 95, e745-e754	6.5	17
367	Neurofilament light chain as biomarker in idiopathic intracranial hypertension. <i>Cephalalgia</i> , <b>2020</b> , 40, 1346-1354	6.1	1
366	Blood platelet RNA enables the detection of multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320946784	2	3
365	Metabolic Age Based on the BBMRI-NL H-NMR Metabolomics Repository as Biomarker of Age-related Disease. <i>Circulation Genomic and Precision Medicine</i> , <b>2020</b> , 13, 541-547	5.2	7
364	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1353-1368	4.3	4
363	Sex differences in CSF biomarkers vary by Alzheimer disease stage and $\epsilon$ genotype. <i>Neurology</i> , <b>2020</b> , 95, e2378-e2388	6.5	20

362	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	3
361	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12063	5.2	5
360	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 912-923	5	26
359	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , <b>2020</b> , 267, 144-152	5.5	11
358	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 44	9	6
357	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , <b>2020</b> , 35, 859-867	7	13
356	Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. <i>Methods in Molecular Biology</i> , <b>2019</b> , 2044, 27-50	1.4	8
355	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 1478-1488	1.2	22
354	Discordant amyloid-IPET and CSF biomarkers and its clinical consequences. <i>Alzheimeris Research and Therapy</i> , <b>2019</b> , 11, 78	9	26
353	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1034-1044	24.1	45
352	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimeris Research and Therapy</i> , <b>2019</b> , 11, 8	9	19
351	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	16
350	Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , <b>2019</b> , 72, 30-38	3.5	37
349	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1035-1048	17.2	237
348	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 997-1004	5.5	13
347	Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV. <i>Scientific Reports</i> , <b>2019</b> , 9, 8004	4.9	8
346	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , <b>2019</b> , 86, 322-324	9.4	8
345	AB4 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , <b>2019</b> , 10, 2240	17.4	20

344	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 817-827	1.2	26
343	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , <b>2019</b> , 92, e2699-e2705	6.5	7
342	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 383-391	5.2	37
341	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 776-787	1.2	74
340	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. <i>Alzheimeris Research and Therapy</i> , <b>2019</b> , 11, 33	9	22
339	ApoE and clusterin CSF levels influence associations between APOE $\epsilon$ genotype and changes in CSF tau, but not CSF A $\beta$ 2, levels in non-demented elderly. <i>Neurobiology of Aging</i> , <b>2019</b> , 79, 101-109	5.6	12
338	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 644-654	1.2	57
337	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 742-753	1.2	50
336	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , <b>2019</b> , 77, 58-65	5.6	9
335	Diurnal Cortisol Secretion Is Not Related to Multiple Sclerosis-Related Fatigue. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1363	4.1	2
334	The appreciation of LED-based white light sources by Dutch and Chinese people in three application areas. <i>Lighting Research and Technology</i> , <b>2019</b> , 51, 353-372	2	9
333	Antibody-based methods for the measurement of $\beta$ synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , <b>2019</b> , 149, 126-138	6	26
332	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , <b>2019</b> , 84, 225-234	5.6	16
331	Plasma proteome in multiple sclerosis disease progression. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1582-1594	5.3	11
330	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , <b>2019</b> , 497, 204-211	6.2	8
329	Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 463-471	5.2	15
328	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , <b>2019</b> , 266, 2535-2545	5.5	6
327	Applying the ATN scheme in a memory clinic population: The ABIDE project. <i>Neurology</i> , <b>2019</b> , 93, e1635-61646	6.6	32

326	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	15
325	Amyloid- $\beta$ peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 83	9	5
324	Cerebrospinal Fluid Amyloid- $\beta$ Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 71, 15-20	4.3	
323	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. <i>Metabolites</i> , <b>2019</b> , 9,	5.6	4
322	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1103-1111	24.1	68
321	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 492-500	6	4
320	Contactins in the central nervous system: role in health and disease. <i>Neural Regeneration Research</i> , <b>2019</b> , 14, 206-216	4.5	23
319	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , <b>2019</b> , 16, 43	5	6
318	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 933-938	6	29
317	Critical Steps to be Taken into Consideration Before Quantification of $\beta$ Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , <b>2019</b> , 8, 129-145	4.6	6
316	PET and CSF amyloid- $\beta$ status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 100	9	17
315	gMS-Classifer1 does not predict disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1010-1011	5	
314	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 292-312	1.2	155
313	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 1-9	5.2	8
312	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 185-193	1.2	19
311	Serum Neurofilament light correlates with CADASIL disease severity and survival. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 46-56	5.3	15
310	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , <b>2018</b> , 90, e1231-e1239	6.5	62
309	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 927-937	5.5	27

308	CNS penetration of ART in HIV-infected children. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 484-489	1.2	12
307	Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2018</b> , 9, 715-726	10.3	32
306	Poly(GP), neurofilament and grey matter deficits in expansion carriers. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 583-597	5.3	29
305	Plasma Amyloid- $\beta$ (A $\beta$ )2) Correlates with Cerebrospinal Fluid A $\beta$ 2 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1857-1863	4.3	61
304	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , <b>2018</b> , 39, 3143-3151	5.9	26
303	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 707-722	1.2	76
302	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 30	9	29
301	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 23	9	13
300	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
299	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 472-480	5	19
298	Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 404-416	5.2	6
297	Upward drift in cerebrospinal fluid amyloid $\beta$ 2 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 62-70	1.2	36
296	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , <b>2018</b> , 19, 244-328	3.8	148
295	Gray matter networks and clinical progression in subjects with prodementia Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 61, 75-81	5.6	29
294	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2018</b> , 61, 198-206	5.6	25
293	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1313-1333	1.2	61
292	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 58	9	13
291	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 1037-1047	5.3	17

290	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 52	9	12
289	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 111	5.3	21
288	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 5	9	63
287	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 104, 183-191	5.2	15
286	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 76	9	56
285	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 309-320	4.3	19
284	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
283	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ -42 Analysis Results. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 576-585	5.5	76
282	O1-10-06: CONTACTIN-1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE <b>2018</b> , 14, P245-P246		
281	F2-02-04: NEUROFILAMENTS TO MEASURE TREATMENT EFFICACY IN MS <b>2018</b> , 14, P604-P604		
280	P2-248: CONTACTIN-2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT <b>2018</b> , 14, P768-P768		
279	P2-228: PRE-ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA <b>2018</b> , 14, P755-P756		
278	O2-04-02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS <b>2018</b> , 14, P621-P622		
277	P1-525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS <b>2018</b> , 14, P533-P533		
276	P1-297: METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE <b>2018</b> , 14, P401-P403		
275	P3-289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EURO-SCD STUDY <b>2018</b> , 14, P1191-P1191		
274	O2-09-03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NON-ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT <b>2018</b> , 14, P641-P642		
273	P3-264: UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION <b>2018</b> , 14, P1176-P1177		

272	DT-02-02: NOVEL ULTRASENSITIVE IMMUNOASSAY DETECTING P-TAU THR217 COMPLETELY DISTINGUISHES ALZHEIMER'S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION <b>2018</b> , 14, P1669-P1669		
271	O2-14-04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE-ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY <b>2018</b> , 14, P657-P658		
270	No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients. <i>Frontiers in Molecular Neuroscience</i> , <b>2018</b> , 11, 371	6.1	2
269	O2-15-06: CSF AMYLOID- $\beta$ PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE <b>2018</b> , 14, P663-P664		
268	O3-14-03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH <b>2018</b> , 14, P1060-P1060		
267	O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS <b>2018</b> , 14, P661-P662		
266	O5-01-03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION <b>2018</b> , 14, P1638-P1639		
265	P2-284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY <b>2018</b> , 14, P789-P790		
264	F4-08-01: PLASMA AMYLOID AS A PRE-SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE <b>2018</b> , 14, P1394-P1394		
263	O2-09-04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF $\beta$ SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH <b>2018</b> , 14, P642-P642		
262	$\beta$ Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , <b>2018</b> , 33, 1724-1733	7	49
261	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , <b>2018</b> , 18, 289	4.1	15
260	Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients. <i>Medical Sciences (Basel, Switzerland)</i> , <b>2018</b> , 6,	3.3	2
259	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 726-736	5.2	8
258	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318819535	2	10
257	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. <i>Brain</i> , <b>2018</b> , 141, 3377-3388	11.2	17
256	P1-247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER IN NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS <b>2018</b> , 14, P373-P373 <sup>1</sup>		
255	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , <b>2018</b> , 15, 41	5	20



254	The plasma peptidome. <i>Clinical Proteomics</i> , <b>2018</b> , 15, 39	5	11
253	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 409	5.3	20
252	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 563-572	5.2	30
251	The Bri2 and Bri3 BRICHOS Domains Interact Differently with A $\beta$ and Alzheimer Amyloid Plaques. <i>Journal of Alzheimeris Disease Reports</i> , <b>2018</b> , 2, 27-39	3.3	11
250	O3-09-06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1-42 AND 1-40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS <b>2018</b> , 14, P1039-P1039		4
249	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , <b>2018</b> , 141, 3443-3456	11.2	49
248	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 107	9	48
247	Clinical phenotype, atrophy, and small vessel disease in $\epsilon$ carriers with Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 91, e1851-e1859	6.5	30
246	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 87	9	8
245	Novel CSF biomarkers to discriminate FTLN and its pathological subtypes. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 1163-1175	5.3	9
244	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , <b>2018</b> , 84, 648-658	9.4	137
243	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 75	9	24
242	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 577-589	15	627
241	Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 1494-1504	1	31
240	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2018</b> , 19, 625-632	5.3	18
239	Characterising user preference for white LED light sources with CIE colour rendering index combined with a relative gamut area index. <i>Lighting Research and Technology</i> , <b>2017</b> , 49, 461-480	2	22
238	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimeris Disease</i> , <b>2017</b> , 56, 687-697	4.3	36
237	Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. <i>Cytokine</i> , <b>2017</b> , 91, 145-152	4	14

236	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 56, 543-555	4.3	7
235	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 143-151	5.2	43
234	How to handle adsorption of cerebrospinal fluid amyloid $\beta$ (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A $\beta$ /A $\beta$ ratio. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 885-892	1.2	44
233	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 903-912	1.2	21
232	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/A $\beta$ 2 cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 201-209	5.2	16
231	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 113-118	5.5	66
230	Unbiased estimates of cerebrospinal fluid $\beta$ amyloid 1-42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 8	9	35
229	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 1226-1236	1.2	45
228	CSF ApoE predicts clinical progression in nondemented APOE $\epsilon$ carriers. <i>Neurobiology of Aging</i> , <b>2017</b> , 57, 186-194	5.6	18
227	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A $\beta$ T-tau, and P-tau values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 45-50	5.2	17
226	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 139-146	5.2	17
225	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 111-126	5.2	128
224	Glutamyl cyclase activity correlates with levels of A $\beta$ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 38	9	18
223	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , <b>2017</b> , 140, 1466-1485	11.2	72
222	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 157-165	6	12
221	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 7, 99-106	5.2	23
220	Low normal cerebrospinal fluid A $\beta$ 2 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , <b>2017</b> , 81, 749-753	9.4	14
219	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 1025-1034	4.3	21

218	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , <b>2017</b> , 74, 1481-1491	17.2	58
217	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 1119-1128	4.3	21
216	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 13333	4.9	33
215	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 201-210	4.3	6
214	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 235	10.1	28
213	Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 257	10.1	11
212	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 73	9	20
211	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV <b>2017</b> , 58, 5985-5992		0
210	The use of cerebrospinal fluid in biomarker studies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2017</b> , 146, 3-20	3	11
209	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 196-207	5.2	39
208	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 108-110	5.2	9
207	[P4146]: NEUROFILAMENT LIGHT CHAIN AND PHOSPHOTAU/TAU RATIO AS CSF BIOMARKERS IN FRONTOTEMPORAL DEMENTIA <b>2017</b> , 13, P1313-P1314		
206	[P4151]: ALPHA-SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER-LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA <b>2017</b> , 13, P1316-P1316		
205	[P2045]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN <b>2017</b> , 13, P705-P706		
204	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 50, 77-86	5.6	3
203	[P1043]: ALPHA-SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES <b>2017</b> , 13, P338-P338		2
202	[P3161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A $\beta$ CLEARANCE? <b>2017</b> , 13, P995-P996		
201	[P3026]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES <b>2017</b> , 13, P1024-P1025		

- 200 [IC-P-005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID- $\beta$  AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS **2017**, 13, P13-P14 1
- 199 [IC-P-055]: EFFECT OF APOE- $\epsilon$  ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE **2017**, 13, P45-P46
- 198 [IC-P-058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P47-P48
- 197 [P1050]: DECISION TREE ANALYSIS REVEALS TWO CUT-OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS **2017**, 13, P342-P343
- 196 [P1076]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY **2017**, 13, P355-P355
- 195 [P2003]: SPPL2B: A NOVEL PROTEIN RELATED TO TAU PATHOLOGY IN ALZHEIMER'S DISEASE? **2017**, 13, P684-P684
- 194 [P2007]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID- $\beta$  AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS **2017**, 13, P688-P688
- 193 [P2042]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES **2017**, 13, P704-P704
- 192 [P2049]: CONTACTIN-1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NON-DEMENTED CONTROLS **2017**, 13, P708-P708
- 191 [P2035]: EFFECT OF APOE  $\epsilon$  ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE **2017**, 13, P748-P750
- 190 [P2038]: ARE NEUROFILAMENT LIGHT CHAIN AND WHITE MATTER INTEGRITY RELATED BIOMARKERS FOR FAMILIAL FRONTOTEMPORAL DEMENTIA? **2017**, 13, P751-P752 1
- 189 [F10304]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P177
- 188 [O10503]: CSF AMYLOID BETA  $\beta$ 2 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS-DEPENDENT UPWARD DRIFT **2017**, 13, P198-P199
- 187 [O10504]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY **2017**, 13, P199
- 186 [O20101]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) **2017**, 13, P547-P548
- 185 [O20501]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P559-P560
- 184 [O20006]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM **2017**, 13, P579
- 183 [O30003]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY **2017**, 13, P924 2

182	[P2194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT <b>2017</b> , 13, P680-P681		
181	[P3075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS <b>2017</b> , 13, P960-P961		
180	Multicenter Analytical Validation of A $\beta$ 0 Immunoassays. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 310	4.1	9
179	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 1061-1066	3.5	13
178	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 159-170	4.3	19
177	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 585-595	4.3	30
176	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 154-163	1.2	129
175	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. <i>Neurology</i> , <b>2016</b> , 86, 50-8	6.5	48
174	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 235-43	5.5	58
173	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 126-9	5.5	66
172	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 287-95	4.3	50
171	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 51-64	4.3	17
170	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , <b>2016</b> , 3, 623-36	5.3	163
169	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau <b>2016</b> , 12, P321-P321		
168	P2-166: Retinal Thickness in Alzheimer's Disease: A Potential Diagnostic Biomarker? Evidence from an Amyloid Proven Early Onset Alzheimer's Disease Cohort <b>2016</b> , 12, P678-P679		1
167	P2-335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples <b>2016</b> , 12, P770-P771		
166	O5-07-02: Personalized Risk Estimates for MCI Patients: Taking Biomarkers Into the Clinic <b>2016</b> , 12, P393-P393		1
165	Validation of soluble amyloid- $\beta$ precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , <b>2016</b> , 137, 112-21	6	15

164	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 7	19	140
163	Cerebral perfusion in the prodementia stages of Alzheimer's disease. <i>European Radiology</i> , <b>2016</b> , 26, 506-84		69
162	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2016</b> , 2, 86-94	5.2	46
161	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 5, 53-65	4	49
160	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A $\beta$ amyloid (1-42) in human cerebrospinal fluid. <i>Alzheimeris and Dementia</i> , <b>2016</b> , 12, 517-26	1.2	179
159	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimeris Disease</i> , <b>2016</b> , 50, 261-70	4.3	12
158	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. <i>Journal of Alzheimeris Disease</i> , <b>2016</b> , 53, 107-16	4.3	5
157	Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3093	1.8	17
156	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , <b>2016</b> , 51, 581-90	4.3	23
155	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients <b>2016</b> , 12, P9-P10		
154	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status <b>2016</b> , 12, P303-P303		
153	IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease <b>2016</b> , 12, P78-P79		
152	P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts <b>2016</b> , 12, P873-P874		
151	P4-112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non-Demented Elderly <b>2016</b> , 12, P1055-P1056		
150	P4-224: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels <b>2016</b> , 12, P1115-P1115		2
149	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease <b>2016</b> , 12, P169-P170		
148	O1-05-02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU <b>2016</b> , 12, P183-P183		
147	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases <b>2016</b> , 12, P355-P355		

146	O5-05-03: Novel CSF Biomarkers Discriminating FTLT-DTP from Non-Demented Controls <b>2016</b> , 12, P388-P388		
145	P1-174: Cost-Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach <b>2016</b> , 12, P469-P470		
144	New CSF biomarkers on the block. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 1118-1119	12	3
143	The inflammatory marker GDF-15 is not independently associated with late-life depression. <i>Journal of Psychosomatic Research</i> , <b>2016</b> , 83, 46-9	4.1	5
142	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , <b>2016</b> , 2, 233-240	6	4
141	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. <i>Bioanalysis</i> , <b>2016</b> , 8, 2243-2254	2.1	10
140	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimeris and Dementia</i> , <b>2015</b> , 11, 1180-90	1.2	201
139	Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 481-4	5	14
138	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2340-7	5.6	40
137	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , <b>2015</b> , 138, 2701-15.2		86
136	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , <b>2015</b> , 138, 918-31	11.2	103
135	Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A $\beta$ by insulin degrading enzyme (IDE) in Alzheimer's disease. <i>Neuroscience Letters</i> , <b>2015</b> , 589, 47-51	3.3	10
134	Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 44, 153-62	4.3	15
133	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
132	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. <i>Neurology</i> , <b>2015</b> , 84, 508-15	6.5	96
131	Standard biobanking conditions prevent evaporation of body fluid samples. <i>Clinica Chimica Acta</i> , <b>2015</b> , 442, 141-5	6.2	9
130	Body fluid biomarkers for multiple sclerosis--the long road to clinical application. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 585-96	15	62
129	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimeris Research and Therapy</i> , <b>2015</b> , 7, 59	9	80

128	Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2015</b> , 864, 79-93	3.6	9
127	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1275-80	17.2	152
126	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins? <b>2015</b> , 11, P644-P644		
125	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2015</b> , 1, 505-12	5.2	62
124	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF) <b>2015</b> , 11, P130-P130		
123	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test <b>2015</b> , 11, P272-P272		
122	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study <b>2015</b> , 11, P606-P607		
121	Amyloid- $\beta$ oligomers relate to cognitive decline in Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 45, 35-43	4.3	34
120	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 48, 711-20	4.3	47
119	Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 44, 809-13	4.3	36
118	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease <b>2015</b> , 11, P414-P414		
117	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 46, 889-99	4.3	11
116	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2015</b> , 1, 75-80	5.2	4
115	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study <b>2015</b> , 11, P297-P297		1
114	Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. <i>Proteomics</i> , <b>2015</b> , 15, 3361-9	4.8	25
113	Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice. <i>Respiratory Research</i> , <b>2015</b> , 16, 119	7.3	6
112	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 179	4.1	223
111	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 202	4.1	16



110	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 216	4.1	31
109	Guidelines on Cerebrospinal Fluid Analysis <b>2015</b> , 407-428		
108	Importance of Pre-analytical Stability for CSF Biomarker Testing <b>2015</b> , 59-77		3
107	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1191-201	1.2	59
106	P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example <b>2015</b> , 11, P387-P387		
105	P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease <b>2015</b> , 11, P873-P873		
104	O4-11-01: Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A $\beta$ (1-42) in human cerebrospinal fluid <b>2015</b> , 11, P295-P296		
103	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design <b>2015</b> , 11, P679-P680		
102	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset <b>2015</b> , 11, P140-P142		
101	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool <b>2015</b> , 11, P254-P255		
100	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease <b>2015</b> , 11, P326-P326		
99	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1605.e13-20	5.6	22
98	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1013-24	5	181
97	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 523-32	1.2	48
96	Techniques, Contraindications, and Complications of CSF Collection Procedures <b>2015</b> , 35-57		7
95	Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. <i>Journal of Proteomics</i> , <b>2014</b> , 106, 191-204	3.9	172
94	Biobanking of CSF: international standardization to optimize biomarker development. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 288-92	3.5	68
93	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 808-17	1.2	132

92	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2014</b> , 6, 27	9	38
91	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 2383-93	5.9	84
90	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , <b>2014</b> , 83, 1210-6	6.5	26
89	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 1596-604	5.6	30
88	Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 533-541	4	14
87	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 713-723.e2	1.2	204
86	The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. <i>Journal of Immunological Methods</i> , <b>2014</b> , 402, 43-9	2.5	48
85	Optimizing patient care and research: the Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 313-27	4.3	243
84	Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 801-7	4.3	93
83	S4-01-04: INTERNATIONAL STANDARDIZATION TO OBTAIN THE BEST POSSIBLE CSF BIOMARKERS <b>2014</b> , 10, P239-P239		
82	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA <b>2014</b> , 10, P300-P300		
81	P4-278: IDENTIFICATION OF NOVEL DIAGNOSTIC CSF PROTEIN BIOMARKERS FOR FTD WITH HIGH DISCRIMINATORY POWER <b>2014</b> , 10, P886-P886		
80	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE <b>2014</b> , 10, P884-P884		
79	Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. <i>PLoS ONE</i> , <b>2014</b> , 9, e100784	3.7	61
78	SUCLG2 identified as both a determinant of CSF A $\beta$ -42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6644-58	5.6	30
77	The Dutch Parelinoer Institute--Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , <b>2014</b> , 14, 254	3.1	42
76	Role of BRI2 in dementia. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 40, 481-94	4.3	15
75	N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , <b>2014</b> , 261, 2338-43	5.5	42

74	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. <i>JAMA Neurology</i> , <b>2014</b> , 71, 855-62	17.2	113
73	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 412-7	5	52
72	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. <i>American Journal of Geriatric Psychiatry</i> , <b>2014</b> , 22, 735-40	6.5	22
71	Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. <i>Journal of Neuroinflammation</i> , <b>2013</b> , 10, 35	10.1	316
70	HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 237-49	14.3	50
69	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 1079-83	3.6	21
68	Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. <i>Journal of Proteomics</i> , <b>2013</b> , 78, 312-25	3.9	52
67	The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. <i>Trials</i> , <b>2013</b> , 14, 250	2.8	31
66	Recent progress in omics-driven analysis of MS to unravel pathological mechanisms. <i>Expert Review of Neurotherapeutics</i> , <b>2013</b> , 13, 1001-16	4.3	4
65	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimeris and Dementia</i> , <b>2013</b> , 9, 251-61	1.2	289
64	O10901: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting <b>2013</b> , 9, P144-P145		
63	Cerebrospinal fluid Aβ2 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimeris and Dementia</i> , <b>2013</b> , 9, 481-7	1.2	139
62	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimeris and Dementia</i> , <b>2013</b> , 9, 276-83	1.2	20
61	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , <b>2013</b> , 80, 1048-56	6.5	131
60	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , <b>2013</b> , 81, 1409-16	6.5	104
59	CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 436-42	5	62
58	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1802-9	5	99
57	Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. <i>PLoS ONE</i> , <b>2013</b> , 8, e70019	3.7	40

56	Neurofilaments as biomarkers in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 552-6	5	148
55	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. <i>Methods</i> , <b>2012</b> , 56, 508-13	4.6	34
54	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimeris and Dementia</i> , <b>2012</b> , 8, 65-73	1.2	210
53	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , <b>2012</b> , 13, 1-10		65
52	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1591-8	5.6	44
51	Microbleeds relate to altered amyloid- $\beta$ metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1011.e1-9	5.6	46
50	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 419-30	2.3	230
49	Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2012</b> , 251, 103-6	3.5	2
48	Increased plasma 8,12-iso-iPF2 $\alpha$ -VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1092-8	5	12
47	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , <b>2012</b> , 79, 1809-16	6.5	110
46	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. <i>Neurology</i> , <b>2012</b> , 78, 47-54	6.5	220
45	Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , <b>2012</b> , 29, 319-27	4.3	54
44	Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 307, 132-8	3.2	16
43	Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 838-50	5	44
42	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimeris and Dementia</i> , <b>2011</b> , 7, 386-395.e6	1.2	291
41	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , <b>2011</b> , 2011, 246412	1.1	40
40	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. <i>European Journal of Neurology</i> , <b>2011</b> , 18, 865-71	6	36
39	The neurofilament light chain is not stable in vitro. <i>Annals of Neurology</i> , <b>2011</b> , 69, 1065-6; author reply 1066-7	9.4	19

38	Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010,	3.7	42
37	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010,	3.7	14
36	Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 129-32	5	5
35	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. <i>Neurology</i> , <b>2010</b> , 75, 1617-22	6.5	50
34	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , <b>2010</b> , 34, 1-12		
33	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , <b>2010</b> , 352, 23-31	2.5	69
32	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. <i>Neurobiology of Disease</i> , <b>2010</b> , 39, 229-41	7.5	56
31	Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. <i>Journal of Neuroscience Methods</i> , <b>2010</b> , 193, 296-9	3	5
30	Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. <i>Neurology</i> , <b>2009</b> , 72, 1322-9	6.5	155
29	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , <b>2009</b> , 73, 1914-22	6.5	470
28	EFNS guidelines on disease-specific CSF investigations. <i>European Journal of Neurology</i> , <b>2009</b> , 16, 760-70	6	65
27	Serum homocysteine levels in relation to clinical progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2008</b> , 79, 1349-53	5.5	34
26	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 479-94	3.8	64
25	CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2007</b> , 23, 225-30	2.6	54
24	24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , <b>2007</b> , 85, 1499-505	4.4	41
23	Endogenous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. <i>Proteomics - Clinical Applications</i> , <b>2007</b> , 1, 1385-92	3.1	32
22	Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2007</b> , 187, 179-86	3.5	45
21	Axonale schade bij multiple sclerose: oorzaken en biologische markerstoffen. <i>Neuropraxis</i> , <b>2007</b> , 11, 27-31		2

20	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. <i>Journal of Neurology</i> , <b>2007</b> , 254, 631-7	5.5	29
19	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. <i>Biomarkers in Medicine</i> , <b>2007</b> , 1, 111-9	2.3	8
18	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , <b>2006</b> , 32, 318-31	5.2	19
17	Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. <i>Lancet Neurology, The</i> , <b>2005</b> , 4, 32-41	24.1	199
16	In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 161, 190-4	3.5	83
15	Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2005</b> , 43, 1089-95	5.9	19
14	Biomarkers for Alzheimer's disease. Which way to go?. <i>Neurobiology of Aging</i> , <b>2004</b> , 25, 695-6	5.6	4
13	Inflammation markers in relation to cognition in a healthy aging population. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 134, 142-50	3.5	224
12	Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. <i>Neuroscience Letters</i> , <b>2003</b> , 347, 159-62	3.3	77
11	Combination of serum markers related to several mechanisms in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2003</b> , 24, 893-902	5.6	70
10	Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. <i>Journal of Nutrition, Health and Aging</i> , <b>2003</b> , 7, 153-9	5.2	46
9	Evaluation of 3-nitrotyrosine as a marker for 3-nitropropionic acid-induced oxidative stress in Lewis and Wistar rats and strain-specific whole brain spheroid cultures. <i>Brain Research</i> , <b>2002</b> , 931, 5-20	3.7	19
8	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. <i>Neurobiology of Aging</i> , <b>2002</b> , 23, 485-508	5.6	159
7	STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM. <i>Cytokine</i> , <b>2002</b> , 19, 228-235	4	79
6	Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. <i>Cytokine</i> , <b>2002</b> , 19, 228-35	4	36
5	Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated Wistar and Lewis rats. <i>Neurochemical Research</i> , <b>2001</b> , 26, 1237-44	4.6	9
4	Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. <i>Neuroscience</i> , <b>2001</b> , 105, 153-67	3.9	54
3	Whole brain spheroid cultures as a model to study the development of nitric oxide synthase-guanylate cyclase signal transduction. <i>Developmental Brain Research</i> , <b>2000</b> , 125, 99-115		13

- |   |  |   |
|---|--|---|
| 2 | Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset    | 1 |
| 1 | Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study | 1 |